|
Welcome
|
|
22 May 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ ...Back to search results ] | [ Print-friendly version ] |
| The use of erythropoietin in cardiac arrest victims: the impact on survival and neurological outcome |
| ISRCTN | ISRCTN67856342 |
| ClinicalTrials.gov identifier | |
| Public title | The use of erythropoietin in cardiac arrest victims: the impact on survival and neurological outcome |
| Scientific title | |
| Acronym | CNMPEPO |
| Serial number at source | CNMPEPO 001 |
| Study hypothesis |
Pre-hospital teams are often confronted with a problem of cardiac arrest patients. Every minute without CPR reduces survival by 10 to 15%. In our pre-hospital setting there is 50% success in returning the spontaneous circulation (Return Of Spontaneous Circulation, ROSC) after CPR. Only half of these patients survive to discharge from hospital.
That is why more thoughts should be pointed to intra- and post-reanimation care meaning preservation and protection of the brain and heart function. Only this provides the chance of survival to be wholesome. Immediately after ROSC there is a period of brain hyperemia. 15 to 30 minutes after ROSC brain perfusion decreases and because the autoregulation of the brain is lost, perfusion of the brain mainly depends upon mean arterial pressure. Brain oedema, focal haemorrhages and instability of circulation lead to further brain ischaemic lesions. The aim of our research is to determine the impact of erythropoietin on survival and neurological outcome of cardiac arrest victims. On the basis of previous preclinical and clinical data about eryrhropoietin (EPO) therapy for acute stroke and acute myocardial infarction we expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart. Hypothesis: The group of patients in cardiac arrest who are treated with erythropoietin have better survival (discharge from hospital) and neurological outcome (Cerebral Performance Category [CPC]). We expect that giving erythropoietin early in the course of cardiopulmonary resuscitation would decrease the ischaemic and reperfusion damage to the brain and heart after a period of cardiac arrest and thus it would improve neurological outcome of these patients. Key questions are: 1. What is the survival rate of the patients who received EPO compared to those who didn't? 2. Does the new approach to the cardiac arrest victims improve their survival? 3. Is there any difference in the neurological outcome between the two groups? |
| Lay summary | |
| Ethics approval | The National Medical Ethics Committee of Republic of Slovenia, approved on 23/01/2007 (ref: KME 37/01/07) |
| Study design | Prospective, multi-centre (three emergency medical service centres) randomised controlled trial. |
| Countries of recruitment | Slovenia |
| Disease/condition/study domain | Cardiac arrest |
| Participants - inclusion criteria |
1. 18 years or older
2. Non-traumatic, cardiac arrest in pre-hospital setting when started with cardiopulmonary reanimation irrespective of initial cardiac rhythm |
| Participants - exclusion criteria |
1. Traumatic cardiac arrest
2. Under 18 years of age 3. Cardiopulmonary Resuscitation (CPR) without drugs (only defibrillation) 4. Pregnancy 5. Severe hypothermia (<30°C) |
| Anticipated start date | 01/06/2007 |
| Anticipated end date | 01/06/2009 |
| Status of trial | Completed |
| Patient information material | |
| Target number of participants | 200 |
| Interventions |
The patients in the intervention group will receive a bolus of EPO (90000 IU) in first four minutes during the CPR process. Intraosseous route is an alternative. Early application of the drug is crucial to cover the period of ischaemia and reperfusion which are both connected with brain in myocardial injury and possibility of malignant heart arrhythmias. In the case of ROSC all the patinets will be cooled down by the process of induced therapeutic hypothermia receiving sterile physiological saline with the temperature of 4°C and the speed 100 ml/hour.
Both intervention and control groups (group with and without erythropoietin) will be treated according the latest guidelines for cardiopulmonary resuscitation (the International Liaison Committee on Resuscitation [ILCOR] - European Resuscitation Council). All the data will be collected under the ILCOR recommendation in Utstein style and checked by two independent researchers. Neurological function of the patients will be assessed and categorized with Cerebral Performance Score (CPS). The following data will also be collected: 1. Capnometry 2. Initial heart rhythm 3. Age 4. Gender 5. Withness of cardiac arrest 6. Lay bystanders CPR 7. Response time 8. Respiratory Rate (RR) 9. Echocardiography 10. Protein S 100 11. Creatinine Kinase (CK) 12. Sodium (Na) 13. Chloride (Cl) 14. Pottasium (K) 15. Calcium (Ca) 16. Magnesium (Mg) 17. Lactate 18. Brain Computed Tomography (CT) |
| Primary outcome measure(s) | Neurological outcome assessed by CPC, from CPC-1 (normal neorological status) to CPC-5 (brain death). This will be measured six months after cardiopulmonary resuscitation. |
| Secondary outcome measure(s) |
1. ROSC in the field (%)
2. ROSC with admission to hospital 3. 24-hour survival 4. Survival (discharge from hospital) |
| Sources of funding | Centre for Health and Emergency Medicine (Zdravstveni dom adolfa drolca maribor) (Slovenia) |
| Trial website | |
| Publications | 2009 results on http://www.ncbi.nlm.nih.gov/pubmed/19371997 |
| Contact name | Prof Štefek Grmec |
| Address | Ulica talcev 9 |
| City/town | Maribor |
| Zip/Postcode | 2000 |
| Country | Slovenia |
| Sponsor | Centre for Health and Emergency Medicine (Zdravstveni dom adolfa drolca maribor) (Slovenia) |
| Address | Ulica talcev 9 |
| City/town | Maribor |
| Zip/Postcode | 2000 |
| Country | Slovenia |
| Sponsor website: | http://www.zd-mb.si/ |
| Date applied | 03/06/2007 |
| Last edited | 21/09/2009 |
| Date ISRCTN assigned | 20/07/2007 |
|
|
|
|
|
| © 2012 ISRCTN unless otherwise stated. | |
|
|
|
|